New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide
作者： Clémence Loiseau , Ashfaq Ali , Raphael Itzykson
DOI: 10.1016/J.EXPHEM.2015.05.014
关键词:
摘要: Recent advances in the treatment of myelodysplastic syndromes have come from use hypomethylating agents decitabine and azacitidine as well immunomodulatory drug lenalidomide. Their clinical benefit has been demonstrated by randomized phase III trials, mostly high-risk del(5q) syndromes, respectively. Neither drug, however, appears to eradicate stem cells, thus they currently do not represent curative options. Here, we review data both translational research on those drugs identify their molecular cellular mechanisms action delineate paths for improved allocation further therapeutic syndromes.
exphem.org
elsevier.com
sci-hub.se 参考文章(152)
Anupama Narla, Shilpee Dutt, J. Randall McAuley, Fatima Al-Shahrour, Slater Hurst, Marie McConkey, Donna Neuberg, Benjamin L. Ebert, Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis Blood. ,vol. 118, pp. 2296- 2304 ,(2011) , 10.1182/BLOOD-2010-11-318543
Ekapun Karoopongse, Cecilia Yeung, John Byon, Aravind Ramakrishnan, Zaneta J. Holman, Peter Y. Z. Jiang, Qiang Yu, H. Joachim Deeg, A. Mario Marcondes, The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy. PLOS ONE. ,vol. 9, ,(2014) , 10.1371/JOURNAL.PONE.0107817
Luis I Sánchez-Abarca, Silvia Gutierrez-Cosio, Carlos Santamaría, Teresa Caballero-Velazquez, Belen Blanco, Carmen Herrero-Sánchez, Juan L García, Soraya Carrancio, Pilar Hernández-Campo, Francisco J González, Teresa Flores, Laura Ciudad, Esteban Ballestar, Consuelo Del Cañizo, Jesus F San Miguel, Jose A Pérez-Simon, None, Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. ,vol. 115, pp. 107- 121 ,(2010) , 10.1182/BLOOD-2009-03-210393
A. Pellagatti, M. Jadersten, A.-M. Forsblom, H. Cattan, B. Christensson, E. K. Emanuelsson, M. Merup, L. Nilsson, J. Samuelsson, B. Sander, J. S. Wainscoat, J. Boultwood, E. Hellstrom-Lindberg, Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients Proceedings of the National Academy of Sciences of the United States of America. ,vol. 104, pp. 11406- 11411 ,(2007) , 10.1073/PNAS.0610477104
C. Muller-Thomas, M. Rudelius, I.-C. Rondak, T. Haferlach, J. Schanz, C. Huberle, B. Schmidt, R. Blaser, M. Kremer, C. Peschel, U. Germing, U. Platzbecker, K. Gotze, Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia Haematologica. ,vol. 99, ,(2014) , 10.3324/HAEMATOL.2014.104760
Yan-Fung Wong, Lars Martin Jakt, Shin-Ichi Nishikawa, Prolonged Treatment with DNMT Inhibitors Induces Distinct Effects in Promoters and Gene-Bodies PLoS ONE. ,vol. 8, pp. e71099- ,(2013) , 10.1371/JOURNAL.PONE.0071099
Wolf-Karsten Hofmann, Andreas Trumpp, Daniel Nowak, Hind Medyouf, Maximilian Mossner, Johann-Christoph Jann, Florian Nolte, Simon Raffel, Carl Herrmann, Amelie Lier, Christian Eisen, Verena Nowak, Bettina Zens, Katja Müdder, Corinna Klein, Julia Obländer, Stephanie Fey, Jovita Vogler, Alice Fabarius, Eva Riedl, Henning Roehl, Alexander Kohlmann, Marita Staller, Claudia Haferlach, Nadine Müller, Thilo John, Uwe Platzbecker, Georgia Metzgeroth, Myelodysplastic Cells in Patients Reprogram Mesenchymal Stromal Cells to Establish a Transplantable Stem Cell Niche Disease Unit Cell Stem Cell. ,vol. 14, pp. 824- 837 ,(2014) , 10.1016/J.STEM.2014.02.014
Oliver C. Goodyear, Mike Dennis, Nadira Y. Jilani, Justin Loke, Shamyla Siddique, Gordon Ryan, Jane Nunnick, Rahela Khanum, Manoj Raghavan, Mark Cook, John A. Snowden, Mike Griffiths, Nigel Russell, John Yin, Charles Crawley, Gordon Cook, Paresh Vyas, Paul Moss, Ram Malladi, Charles F. Craddock, Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML) Blood. ,vol. 119, pp. 3361- 3369 ,(2012) , 10.1182/BLOOD-2011-09-377044
Claude Preudhomme, Marie-Joelle Mozziconacci, Hugues de The, Jacqueline Lehmann-Che, Pierre Fenaux, Cecile Bally, Lionel Adès, Aline Renneville, Marie Sebert, Virginie Eclache, Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leukemia Research. ,vol. 38, pp. 751- 755 ,(2014) , 10.1016/J.LEUKRES.2014.03.012
Josephine Aimiuwu, Hongyan Wang, Ping Chen, Zhiliang Xie, Jiang Wang, Shujun Liu, Rebecca Klisovic, Alice Mims, William Blum, Guido Marcucci, Kenneth K. Chan, RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood. ,vol. 119, pp. 5229- 5238 ,(2012) , 10.1182/BLOOD-2011-11-382226